OPTN OptiNose Inc.

6.45
-0.65  -9%
Previous Close 7.09
Open 7.06
52 Week Low 3.28
52 Week High 11.66
Market Cap $296,094,745
Shares 45,906,162
Float 23,690,600
Enterprise Value $283,231,219
Volume 859,742
Av. Daily Volume 534,566
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
XHANCE
Chronic sinusitis
Phase 3
Phase 3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
XHANCE
Nasal polyps - pediatric
Phase 3
Phase 3
Commencement of enrolment announced December 10, 2018.
XHANCE
Nasal polyps
Approved
Approved
Approval announced September 18, 2017 (prior to IPO).

Latest News

  1. YARDLEY, Pa., June 30, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced initiation of development of a new product candidate, OPN-019. OPN-019 will combine the Company's proprietary nasal Exhalation Delivery System (EDS) technology with an antiseptic that has been recently shown in vitro to kill the virus that causes COVID-19.

    Because components of the drug-device combination product candidate, including both the active drug and delivery device, are currently commercially available in the U.S., the Company expects to be able to rapidly progress to a meeting with FDA to discuss an IND and then onward to clinical trials…

    YARDLEY, Pa., June 30, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced initiation of development of a new product candidate, OPN-019. OPN-019 will combine the Company's proprietary nasal Exhalation Delivery System (EDS) technology with an antiseptic that has been recently shown in vitro to kill the virus that causes COVID-19.

    Because components of the drug-device combination product candidate, including both the active drug and delivery device, are currently commercially available in the U.S., the Company expects to be able to rapidly progress to a meeting with FDA to discuss an IND and then onward to clinical trials. The Company is focused on supporting the initial stages of development within its current operating expense plan and intends to seek grants, partnerships, and/or other sources of capital to fund future development.

    "The medical community is still learning about COVID-19, but we think the virus frequently spreads from one person's upper airways - by coughing, sneezing, or talking for example - to another person's upper airways, especially the nose. That is why we wear masks and socially distance. Evidence suggests that the virus attaches to certain types of cells in the deep part of the nose, and can multiply for an extended period, often days, before symptoms appear – all the while risking spread to others," stated Ramy Mahmoud, M.D., MPH, President and Chief Operating Officer of Optinose. "Recently, this antiseptic has been shown to kill the COVID-19 virus, which leaves the problem of how to coat the deep lining of the nasal cavity with the drug, which is very difficult with standard approaches like nasal sprays. That is where our unique EDS technology comes in. We have demonstrated that an EDS can spread medicine thoroughly in the deep areas of the nasal cavity where the virus appears to be multiplying and shedding. With OPN-019, we want to offer people a safe antiseptic/antiviral combined with an EDS device that enables them to deliver it to surfaces deep in the nasal cavity."

    "Today, someone with or without symptoms who tests positive is often sent home. Our intent is for OPN-019 to offer that person a way to reduce their own risk of disease progression and also help members of their household - or other at-risk people - avoid getting sick at all. It could help fill the gap between vaccines, which are for healthy people to prevent infection, and drugs that are used for very sick people who may have to be hospitalized," explained Dr. Mahmoud, adding, "We picked an antiseptic/antiviral that has been known for years to kill many viruses. With new third party research showing that it can kill the SARS-CoV-2 virus, we are excited about the potential for OPN-019 to work against COVID-19. The bottom line is that we aim to give doctors a way to suppress virus multiplication and reduce viral load and the duration of shedding from the upper airways so that we can reduce progression of asymptomatic or mildly symptomatic disease, reduce transmission to others, and protect people by giving them post-exposure or high-risk prophylaxis."

    "We are very interested in the potential of this drug-device combination to help combat a public health crisis," said David A. Gudis, M.D., Chief of the Division of Rhinology and Anterior Skull Base Surgery in the Department of Otolaryngology at Columbia University, who has no financial relationship with Optinose. "An intervention with potential to reduce virus load, limit replication, and decrease upper airway viral shedding could have enormous implications. I am excited about Optinose's EDS, which may represent such a weapon in the fight against SARS-CoV-2. As the proposed antiseptic it delivers has been shown to kill not only coronaviruses and influenzae, but also many other viruses, bacteria and even fungi, this intervention may represent a treatment pathway for other upper airway infections in the future as well."

    About Optinose

    Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose, and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.

    Cautionary Note on Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others, statements relating to the Company's development plans and objectives for OPN-019; the potential benefits of OPN-019 for the treatment and prevention of COVID-19 and other upper airway infections; the potential benefits of the Company's EDS technology; the Company's intention to fund initial development of OPN-019 within its current operating expense plan and to seek grants, partnerships and/or other sources of capital to fund future development; and other statements regarding the Company's future operations, prospects, objectives and other future events. Forward-looking statements are based upon management's current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: unknowns relating to COVID-19 and the virus that causes COVID-19; risks, uncertainties and delays relating to product development, the enrollment, completion and results of clinical trials and the regulatory approval process; risks that results seen in preclinical studies may not be replicated in humans; unanticipated product development costs and expenses; intense competition for vaccines and other therapies for COVID-19; and the risks, uncertainties and other factors discussed under the caption "Item 1A. Risk Factors" and elsewhere in the Company's most recent Form 10-K and Form 10-Q filings with the Securities and Exchange Commission - which are available at www.sec.gov. As a result, you are cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statements made in this press release speak only as of the date of this press release, and the Company undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise.

    Optinose Investor Contact

    Jonathan Neely



    267.521.0531

    Primary Logo

    View Full Article Hide Full Article
  2. YARDLEY, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 9:00 a.m. ET.

    To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website.

    A replay of the webcast will be available for 30 days following the conclusion of the event.

    About Optinose
    Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy…

    YARDLEY, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 9:00 a.m. ET.

    To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website.

    A replay of the webcast will be available for 30 days following the conclusion of the event.

    About Optinose

    Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.

    Optinose Investor Contact

    Jonathan Neely



    267.521.0531

    Primary Logo

    View Full Article Hide Full Article
  3. YARDLEY, Pa., June 19, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the Company has been named one of the Philadelphia Business Journal's "Best Places to Work" for 2020 in the medium-sized company category for the third year in a row.

    "We are extremely proud of the culture we have built at Optinose over the last ten years. Even during these extraordinary times, maintaining a fun and productive work environment in which people can come together and accomplish great things continues to be our highest priority," said Peter Miller, CEO of Optinose. "We are excited to be recognized once again as a ‘Best…

    YARDLEY, Pa., June 19, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the Company has been named one of the Philadelphia Business Journal's "Best Places to Work" for 2020 in the medium-sized company category for the third year in a row.

    "We are extremely proud of the culture we have built at Optinose over the last ten years. Even during these extraordinary times, maintaining a fun and productive work environment in which people can come together and accomplish great things continues to be our highest priority," said Peter Miller, CEO of Optinose. "We are excited to be recognized once again as a ‘Best Place to Work' by the Philadelphia Business Journal. Our goal is that each colleague feels a deep connection to what they do, loves coming to work and is aligned to our One Mission – to improve lives."

    "Public recognition of Optinose as a ‘Best Place to Work' is an honor for all of us, and is only possible because of the collective commitment and contributions of our team," added Ramy Mahmoud, MD, President and Chief Operating Officer of Optinose. "It is especially heartening that even during this uniquely fraught time in history, nearly 84% of our colleagues chose to participate in this year's survey. We truly value colleague feedback and make concrete action plans based on the feedback from this survey. Employee engagement is a top priority: it starts with our hiring process and permeates everything we do thereafter. Nurturing a team of high-achieving professionals who are passionately motivated to improve human health, and who share clearly articulated core values, is essential to our success in developing and commercializing innovative new products."

    Optinose has grown tremendously over the past several years, and currently has more than 200 colleagues, with nearly 80 based in the headquarters in Yardley. The Company has achieved key objectives in support of the launch of its lead product XHANCE® and the conduct of multiple clinical trials. More information about the shared purpose that unites the people of Optinose is here, and more information about career opportunities is here.

    The Philadelphia Business Journal names companies to its "Best Places to Work" list using a rigorous scientific process based on responses to an independent employee engagement survey conducted by Quantum Workplace. As part of the survey, employees rate the company in areas including communication and resources, individual needs, manager effectiveness, personal engagement, team dynamics, and trust in leadership.

    About Optinose

    Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.

    Optinose Investor Contact

    Jonathan Neely



    267.521.0531

    Primary Logo

    View Full Article Hide Full Article
  4. YARDLEY, Pa., May 27, 2020 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN) today announced that due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic and recommendations and orders from federal and state governmental authorities, its Annual Meeting of Stockholders (the 2020 Annual Meeting) will now be held by means of a virtual format only. The date and time of the meeting (June 10, 2020 at 8:30 am Eastern Time), as disclosed in Optinose's proxy statement for the meeting, have not changed.

    Online access to the meeting will begin at 8:15 am Eastern Time. Stockholders will not be able to attend the meeting in person. The virtual format of the 2020 Annual Meeting will provide stockholders with the…

    YARDLEY, Pa., May 27, 2020 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN) today announced that due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic and recommendations and orders from federal and state governmental authorities, its Annual Meeting of Stockholders (the 2020 Annual Meeting) will now be held by means of a virtual format only. The date and time of the meeting (June 10, 2020 at 8:30 am Eastern Time), as disclosed in Optinose's proxy statement for the meeting, have not changed.

    Online access to the meeting will begin at 8:15 am Eastern Time. Stockholders will not be able to attend the meeting in person. The virtual format of the 2020 Annual Meeting will provide stockholders with the same rights and opportunities to participate as they would have at an in-person meeting. If you plan to attend the meeting, please check the "Investors" section of www.optinose.com for updates prior to the meeting date.

    As always, whether or not you plan to attend the 2020 Annual Meeting, you are encouraged to vote your shares prior to the meeting by one of the methods described in the proxy materials for the meeting. If you have already voted, you do not need to vote again.

    Attending the Virtual Meeting
    You can attend the meeting by accessing www.virtualshareholdermeeting.com/OPTN2020 and entering the 16-digit control number on the proxy card you previously received; if you hold your shares in "street name" (i.e., through an account at a broker or other nominee), please follow your broker's or nominee's instructions you previously received to obtain your 16-digit control number or otherwise attend through the broker or nominee.

    A list of Optinose's stockholders of record will be available for examination by stockholders on the meeting website during the meeting.

    Asking Questions
    If you wish to submit a question during the meeting, you can do so by visiting www.virtualshareholdermeeting.com/OPTN2020 and entering your 16-digit control number and submitting the question in the "Ask a Question" field.  Only questions pertinent to meeting matters will be answered during the meeting, subject to time constraints.

    Voting Shares at the Virtual Meeting
    If you have not voted your shares prior to the meeting, you will be able to vote your shares electronically at the 2020 Annual Meeting by clicking "Vote Here" on the meeting website. Whether or not you plan to attend the meeting, you are encouraged to vote your shares prior to the meeting by one of the methods described in the proxy materials you previously received.

    The proxy materials you previously received may continue to be used to vote your shares in connection with the meeting. The previously distributed proxy materials will not be updated to reflect the change to a virtual format. If you have already voted, you do not need to vote again.

    About Optinose
    Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.

    Optinose Investor Contact
    Jonathan Neely

    267.521.0531

    Primary Logo

    View Full Article Hide Full Article
  5. YARDLEY, Penn., May 26, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the 2020 Jefferies Virtual Healthcare Conference on June 2, 2020, at 1:30 p.m. ET.

    To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website.

    A replay of the webcast will be available for 30 days following the conclusion of the event.

    About Optinose
    Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists…

    YARDLEY, Penn., May 26, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the 2020 Jefferies Virtual Healthcare Conference on June 2, 2020, at 1:30 p.m. ET.

    To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website.

    A replay of the webcast will be available for 30 days following the conclusion of the event.

    About Optinose
    Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.

    Optinose Investor Contact
    Jonathan Neely

    267.521.0531

    Primary Logo

    View Full Article Hide Full Article
View All OptiNose Inc. News